Treatment-limiting toxicities associated with nucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study

Current Therapeutic Research - Clinical and Experimental

Volumn 66, Issue 2, 2005, Pages 117-129

  Palacios, Rosario ^a   Santos, Jesús ^a   Camino, Xavier ^b   Arazo, Piedad ^c   Torres Perea, Rafael ^d   Echevarría, Santiago ^e   Ribera, Esteban ^f   Sánchez De La Rosa, Rainel ^g   Moreno Guillen, Santiago ^h  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL SEVERO OCHOA   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Abacavir; AIDS; Didanosine; Highly active antiretroviral therapy; HIV 1 infection; Lamivudine; Nucleoside analogue reverse transcriptase inhibitor toxicity; Stavudine; Tenofovir; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; ASTHENIA; CLINICAL OBSERVATION; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG ERUPTION; DRUG USE; EXPERIENCE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; LABORATORY; LACTIC ACIDOSIS; LEUKOPENIA; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MYALGIA; NAUSEA; PANCREATITIS; PATIENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TOXICITY; VIRUS LOAD; VOMITING;

EID: 20444386580     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2005.04.002     Document Type: Article

References (27)

1. Dieterich D.T. Long-term complications of nucleoside reverse transcriptase inhibitor therapy AIDS Read 13 2003 176 184
2. Dieterich D.T. Long-term complications of nucleoside reverse transcriptase inhibitor therapy AIDS Read 13 2003 187
3. Palella F.J. Jr, Delaney K.M., and Moorman A.C. HIV Outpatient Study Investigators Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 1998 853 860
4. Carr A., and Cooper D.A. Adverse effects of antiretroviral therapy Lancet 356 2000 1423 1430
5. Carr A., Samaras K., and Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 1998 F51 F58
6. Safrin S., and Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection AIDS 13 1999 2493 2505
7. Ammassari A., Antinori A., Cozzi-Lepri A. AdlCoNA Study Group LipolCoNA Study Group Relationship between HAART adherence and adipose tissue alterations J Acquir Inmune Defic Syndr 31 Suppl 3 2002 S140 S144
8. Viraben R., and Aquilina C. Indinavir-associated lipodystrophy AIDS 12 1998 F37 F39
9. Carr A., Samaras K., Chisholm D.J., and Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance Lancet 351 1998 1881 1883
10. Saint-Marc T., Partisani M., and Poizot-Martin I. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy AIDS 13 1999 1659 1667
11. Mallal S.A., John M., and Moore C.B. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection AIDS 14 2000 1309 1316
12. Brinkman K., Smeitink J.A., Romijn J.A., and Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis ofantiretroviral-therapy-related lipodystrophy Lancet 354 1999 1112 1115
13. Brinkman K. Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors Clin Infect Dis 31 2000 167 169
14. Walker U.A., Setzer B., and Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors AIDS 16 2002 2165 2173
15. Drechsler H., and Powderly W.G. Switching effective antiretroviral therapy: A review Clin Infect Dis 35 2002 1219 1230
16. Castro K.G., Ward J.W., and Slutsker L. Centers for Disease Control and Prevention, National Center for Infectious Diseases Division of HIV/AIDS Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults MMWR Morb Mortal Wkly Rep 18 1993 RR 17 1992
17. Gerschenson M. Mitochondria and lipodystrophy: Where are we now? Antivir Ther 8 2003 261 263
18. Carr A., Workman C., Smith D.E. Mitochondrial Toxicity (MITOX) Study Group Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial JAMA 288 2002 207 215
19. Carr A., Samaras K., and Thorisdottir A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study Lancet 353 1999 2093 2099
20. Lewis W. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: Experimental clarifications and persistent clinical questions Antiviral Res 58 2003 189 197
21. Moyle G., and Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities HIV Clin Trials 3 2002 89 98
22. Martinez E., Arnaiz J.A., and Podzamczer D. Nevirapine Efavirenz, and Abacavir (NEFA) Study Team Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection N Engl J Med 349 2003 1036 1046
23. Martin A., Smith D.E., Carr A. Mitochondrial Toxicity Study Group Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study AIDS 18 2004 1029 1036
24. Presented at Moyle G., Sabin C., and Cartledge J. A 48-week, randomized, open-label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART Boston, Mass. Late Breaker 44 12th Conference on Retroviruses and Opportunistic Infections 2005 Boston, Mass. Late Breaker 44
25. Poster presented at Ribera E., Paradineiro J., and Sauleda S. Improvement of subcutaneous fat, lipid profile and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine isswitched to tenofovir: The Lipotest Study Boston, Mass. Poster 860 12th Conference on Retroviruses and Opportunistic Infections 2005 Boston, Mass. Poster 860
26. Poster presented at Milinkovic A., Lopez S., and Vidal S. A randomized open study comparing the impact of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving anti retroviral therapy containing stavudine Boston, Mass. Poster 857 12th Conference on Retroviruses and Opportunistic Infections 2005 Boston, Mass. Poster 857
27. Domingo P., Labarga P., Palacios R. Recover Study Group Improvement of dyslipidemia in patients switching from stavudine to tenofovir: Preliminary results AIDS 18 2004 1475 1478